RecruitingNot ApplicableNCT06582199

Precision Medicine in Alzheimer's Disease : Integration of Resilience Metrics and Risk Factors - Validation Cohort BioCogBank-AD

Precision Medicine in Alzheimer's Disease: Integration of Resilience Metrics and Risk Factors - Validation Cohort BioCogBank-AD

Sponsor

Assistance Publique - Hôpitaux de Paris

Enrollment

244 participants

Start Date

Oct 31, 2024

Study Type

INTERVENTIONAL

Conditions

Alzheimer Disease

Summary

BioCogBankAD aims at building a prospective clinical practice cohort of 244 patients with biologically confirmed mild cognitive impairment due to Alzheimer's Disease (AD) or mild AD in order to validate data regarding markers of resilience toward AD pathophysiological process discovered in an upstream project called AD-Resilience.

Eligibility

Min Age: 50 YearsMax Age: 90 Years

Plain Language Summary

Simplified for easier understanding

This study tracks a group of people already diagnosed with Alzheimer's disease to better understand what factors help some people cope better with the disease than others — called "resilience." By collecting brain scans, spinal fluid, blood, and cognitive test results, researchers hope to find protective factors that could be targeted in future treatments. **You may be eligible if...** - You have been diagnosed with Alzheimer's disease according to established international criteria - You are between 50 and 90 years old - You have abnormal Alzheimer's biomarkers in your spinal fluid - Your cognitive impairment is mild (MMSE score of 20 or higher) - Brain MRI data is available **You may NOT be eligible if...** - You have another neurological condition that explains your symptoms - You have severe cognitive impairment - You are unable to complete the neuropsychological assessments Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERBlood sample

Plasma, DNA, RNA and PBMC Sampling

BEHAVIORALNeuropsychological battery tests

* Short term memory: Digit span (forward and backward) * Long term memory: Free and Cued selective reminding Test * Language and semantic Memory : Verbal Fluency (Category and Litteral), Image Naming (DO 40) * Praxis * Visuo Spatial abilities: Rey-Osterrieth Complex Figure Test * Attention and executive functions: Trail Making Test (TMT) Part A and B, Frontal Assessment Battery (FAB) * Autonomy in daily life activities : Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL), Instrumental Activities of Daily Living (IADL) * Mood and anxiety: Hospital Anxiety and Depression Scale (HADS) * Cognitive reserve : Cognitive Reserve Index questionnaire (CRIq)

Locations(1)

Hôpital Cochin

Paris, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06582199

Related Trials

Motor Slowing and Its Lesion-related Correlates in Alzheimer's Disease

NCT028116531 location

Study of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease

NCT072213443 locations

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)

NCT07011745140 locations

Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.

NCT067813331 location

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

NCT06585787289 locations